Chronobiology, Sleep Related Risk Factors and Light Therapy in Perinatal Depression: the Life-ON Project

March 3, 2021 updated by: Mauro Manconi, Ospedale Regionale di Lugano

In a 3 years longitudinal, observational, multicentre study, about 500 women will be recruited and followed-up from early pregnancy (10-15 gestational week) until 12 months after delivery. The primary aim of the present study is to systematically explore and characterize risk factors for perinatal depression (PND) by prospective sleep assessment (using wrist actigraphy, polysomnography and various sleep questionnaires) and blood based analysis of potential markers during the perinatal period (Life-ON study). Secondary aims are to explore the relationship between specific genetic polymorphisms and PND (substudy Life-ON1), to investigate the effectiveness of BLT in treating PND (substudy Life-ON2) and to test whether a short term trial of BLT during pregnancy can prevent PND (substudy Life-ON3).

The characterization of specific predictive and risk factors for PND may substantially contribute to improve preventive medical and social strategies for the affected women. The study results are expected to promote a better understanding of the relationship between sleep disorders and the development of PND and to confirm, in a large sample of women, the safety and efficacy of BLT both in prevention and treatment of PND.

Study Overview

Study Type

Interventional

Enrollment (Actual)

450

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Ticino
      • Lugano, Ticino, Switzerland, 6900
        • Neurocenter of Southern Switzerland

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 45 years (Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

Female

Description

Inclusion Criteria:

  • Medically healthy
  • Normal ocular function
  • Gestational age between 10 to 15 weeks at time of screening
  • Written informed consent

Exclusion Criteria:

  • Diagnosis of bipolar I or II disorder (DSM-5)
  • Recent history (less than 6 months) or current major depression or an Edinburgh Postnatal Depression Scale (EPDS) score > 12 at time of inclusion
  • Any psychotic episode, substance abuse, recent history of suicide attempt (less than 12 months)
  • Use of antidepressants or other pharmacologic treatments for depression in the last 6 months
  • Fetal malformations and intrauterine fetal death

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Single Group Assignment
  • Masking: Double

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Bright light therapy (BLT)
Bright light therapy (10'000 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
Bright light therapy (10'000 lux) for 60 minutes after wake-up
Placebo dim light (500 lux) for 60 minutes after wake-up
Placebo Comparator: Placebo dim light
Placebo dim light (50 lux) for 30 minutes after wake-up using Philips EnergyUp EnergyLight HF3419/01
Bright light therapy (10'000 lux) for 60 minutes after wake-up
Placebo dim light (500 lux) for 60 minutes after wake-up

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Change in Depression Score as assessed by the Edinburgh Postnatal Depression Scale (EPDS)
Time Frame: during 6 weeks of light treatment plus 12 months observation
during 6 weeks of light treatment plus 12 months observation
Change in Depression Score as assessed by the Hamilton Depression Rating scale - 21 items (HDRS-21)
Time Frame: during 6 weeks of light treatment plus 12 months observation
during 6 weeks of light treatment plus 12 months observation
Change in Depression Score as assessed by the Montgomery-Asberg Depression Rating Scale (MADRS)
Time Frame: during 6 weeks of light treatment plus 12 months observation
during 6 weeks of light treatment plus 12 months observation

Secondary Outcome Measures

Outcome Measure
Time Frame
Objective sleep-related markers and risk factors for perinatal depression as assessed by home polysomnography
Time Frame: at 23th-25th week of gestation
at 23th-25th week of gestation
Objective sleep-related markers and risk factors for perinatal depression as assessed by wrist actigraphy
Time Frame: observation over a period of 2 years
observation over a period of 2 years
Analysis of genetic risk factors for perinatal depression by single blood test
Time Frame: at 23th-25th week of gestation
at 23th-25th week of gestation
Subjective mood changes as assessed by the Visual Analog Scale for Depression (VAS)
Time Frame: during 6 weeks of light treatment plus 12 months observation
during 6 weeks of light treatment plus 12 months observation
Number of participants with treatment-related adverse events as assessed by the Systematic Assessment for Treatment Emergent Events (SAFTEE)
Time Frame: during 6 weeks of light treatment plus 12 months observation
during 6 weeks of light treatment plus 12 months observation

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

May 1, 2016

Primary Completion (Actual)

November 1, 2018

Study Completion (Actual)

November 1, 2020

Study Registration Dates

First Submitted

January 13, 2016

First Submitted That Met QC Criteria

January 22, 2016

First Posted (Estimate)

January 27, 2016

Study Record Updates

Last Update Posted (Actual)

March 4, 2021

Last Update Submitted That Met QC Criteria

March 3, 2021

Last Verified

March 1, 2021

More Information

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Depressive Disorder

Clinical Trials on Philips EnergyUp EnergyLight HF3419/01

3
Subscribe